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Abstract
UV exposure and p53 mutations are major factors in non-melanoma skin cancer, whereas a role for HPV infections has not
been defined. Previous data demonstrated the wtp53-mediated degradation of cutaneous HPV20E6 by caspase-3. DNp63a
and hot-spot mutant p53R248W conveyed a protective effect on HPV20E6 under these conditions. We demonstrate a
differential regulation by wtp53 of the E6 genes of cutaneous types HPV4, HPV5, HPV7, HPV27, HPV38, HPV48, HPV60 and
HPV77. Caspase- or proteasome-mediated down-regulation was HPV type dependent. Mutant p53R248W up-regulated
expression of all these E6 proteins as did DNp63a except for HPV38E6 which was down-regulated by the latter. None of
these cellular proteins affected HPV41E6 expression. Ectopic expression of both mutp53R248W and DNp63a in the normal
NIKS keratinocyte cell line harbouring endogenous p53 and p63however led to a down-regulation of HPV20E6. We
demonstrate that HPV20E6 expression in these cells is modulated by additional, yet unidentified, cellular protein(s), which
are not necessarily involved in apoptosis or autophagy. We further demonstrate proliferation of HPV20E6-expressing
keratinocytes. Levels of proteins involved in cell cycle control, cyclin-D1, cdk6 and p16
INK4a, phosphorylated pRB, as well as
c-Jun and p-c-Jun, were all increased in these cells. HPV20E6 did not compete for the interaction between p16
INK4a with
cyclin-D1 or cdk6. Phosphorylation of pRB in the HPV20E6 expressing cells seems to be sufficient to override the cytokenetic
block induced by the p16
INK4a/pRB pathway. The present study demonstrates the diverse influence of p53 family members
on individual cutaneous HPVE6 proteins. HPV20E6 expression also resulted in varying protein levels of factors involved in
proliferation and differentiation.
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Introduction
Cutaneous papillomaviruses (HPV) have been associated with
the pathogenesis of non-melanoma skin cancer. The wide
spectrum of HPV types demonstrated by DNA detection in
malignant lesions also occurs in normal skin [1–8]. The
mechanism by which these viruses contribute to malignant disease
remains unclear. A crucial function of high-risk mucosal HPV E6
in the pathogenesis of malignant tumors is targeting a number of
cellular proteins, including wtp53, for proteasomal degradation
[9–12]. Cutaneous HPVs do not induce proteasome-mediated
degradation of p53 or PDZ-domain proteins [11,13,14]. The
majority of so-called cutaneous HPV types belong phylogenetically
to the genera Beta- and Gamma-papillomaviruses, although a few
types which are mainly associated with benign lesions of the skin,
group within the genus Alpha-papillomavirus [15,16]. Evidence
on the molecular activity of single cutaneous HPV types is slowly
emerging. Recent results indicate that the activation of telomerase
by HPV38E6 may prolong the lifespan of human keratinocytes
[17,18]. A number of cutaneous HPV types, in contrast to others,
have transforming potential in rodent cells [19,20].
UV-exposure and mutations in wtp53 are considered as co-
factors in the pathogenesis of non-melanoma skin cancer [21,22].
A number of p53 mutations have been termed ‘‘hot-spot’’
mutations due to their frequent association with respective tumor
types [23]. p53 mutantR248W is a UV-induced ‘‘hot-spot’’
mutation in non-melanoma skin cancer. Mutant p53 binds to
promoters to form transcriptionally active complexes, thereby
gaining function [24,25]. The contact-mutant p53R248W exerts a
dominant-negative effect through tetramerization with wtp53 and
other p53 family members, with re-localization of this complex to
the nucleus [26].
TAp63a and DNp63a play an important role in proliferation
and differentiation of the skin and the ratio between these two
isoforms determines the biological outcome. Increased level of
DNp63aleads to failure of differentiation and the organization of
the epithelium [27]. Proliferation and differentiation defects in the
skin of p63-null mice were rescued by the direct down-regulation
of p16
INK4a expression by p63 [28]. DNp63a acts as a dominant
negative by inhibiting p53, TAp63 and TAp73 trans-activation
and thus apoptosis [29,30] and is over-expressed in several tumors
including the majority of squamous cell carcinomas [31–33].
E6 gene expression of several cutaneous HPV types protected
keratinocytes from UV-B induced apoptosis [34–36] by mediating
degradation [34] or a reduction in the levels of pro-apoptotic Bak
[37] and thereby preventing the release of pro-apoptotic factors
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caspase-dependent degradation of HPV20E6 was rescued by
mutant p53R248W and DNp63a and other unknown proteins
involved in proteasome degradation [13]. We now investigated
whether similar interactions between mutant p53R248W, wtp53
and DNp63a with E6 of other cutaneous HPV types occurred, as
we had previously demonstrated a type specific, rather than genus-
or species-specific UV-induced activation or suppression of a
number of cutaneous HPV promoters [36,39]. The present study
demonstrates a differential regulation of the E6 genes of cutaneous
types HPV4, HPV5, HPV7, HPV27, HPV38, HPV48, HPV60
and HPV77 by wtp53. Caspase- or proteasome-mediated down-
regulation was HPV type dependent. The majority of these E6
proteins were upregulated by both mutant p53R248W and
DNp63a. An exception was HPV38E6 which was down-regulated
by DNp63a. None of these cellular proteins affected the expression
of HPV41E6. These data were obtained by over-expression in the
p53-null H1299 cell line. We continued to examine whether
similar observations could be made in human keratinocytes with
endogenous wtp53 and p63. We limited these further studies to the
expression of HPV20E6 in human keratinocytes. Ectopic
expression of both mutp53R248W and DNp63a in the normal
NIKS keratinocyte cell line harbouring endogenous p53 and p63
however led to a down-regulation of HPV20E6. We demonstrate
that HPV20E6 expression in these cells is modulated by
additional, yet unidentified, cellular protein(s) which are not
necessarily involved in apoptosis or autophagy. We further
demonstrate proliferation of HPV20E6-expressing keratinocytes.
Levels of proteins involved in cell cycle control, cyclin-D1, cdk6
and p16
INK4a, phosphorylated pRB, as well as c-Jun and p-c-Jun,
were all increased in these cells. HPV20E6 did not compete for the
interaction between p16
INK4a with cyclin-D1 or cdk6. Phosphor-
ylation of pRB in the HPV20E6 expressing cells seems to be
sufficient to override the cytokenetic block induced by the
p16
INK4a/pRB pathway.
Materials and Methods
Expression vectors
Plasmid constructs pcDNA3.1(+)-mtp53R248W, pcDNA3.1(+)-
wtp53 and pcDNA3.1(+)-DNp63a were described previously [40].
N- and C-terminal flag-tagged HPV4E6, HPV5E6, HPV7E6,
HPV20E6, HPV27E6, HPV38E6, HPV41E6, HPV48E6,
HPV60E6 and HPV77E6 were obtained by PCR amplification
using the respective complete genome as template (primers in
Table S1) [13,41]. All amplified products were cloned into vector
pcDNA3.1(+) from Invitrogen (Karlsruhe, Germany). Sequences
of all DNA inserts and their orientation were verified by
sequencing of the constructs. pLXSN-flagHPV20E6 was con-
structed by cloning PCR amplified flag-tagged HPV20E6 into the
pLXSN vector as previously described [41].
Cell culture and transfection assays
H1299 cells (non-small cell lung carcinoma, p53-null, ATCC)
were transfected with the respective HPV-E6 constructs as
described previously [40]. Empty vector pcDNA3.1 (+) was used
to equalize the total amount of transfected DNA in all samples and
transfection efficiency was measured by co-expression of b-
galactosidase (pCMV-b-gal). pLXSN without HPV20E6 was used
as negative control in comparison with pLXSN-flag20E6.
Retrovirus production and infection of NIKS cells
The spontaneously immortalized human foreskin keratinocyte
cell line NIKS (Stratatech, Madison, USA) [42] was used for
expression of HPV20E6. This cell line was maintained as sub-
confluent cultures on a mitomycin C-treated fibroblast feeder layer
in NIKS medium (3:1 Ham’s F-12 medium and Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% FCS,
24 mg/adenine, 8,4 ng/ml cholera toxin, 10 ng/ml epidermal
growth factor (EGF), 0,4 mg/ml hydrocortisone, 5 mg/ml insulin
and 1% penicillin/streptomycin). NIKS cells were infected with
pLXSN-flagHPVE6 retrovirus and pooled after selection with
G418 as previously described [41]. The pooled cells (pLXSN and
pLXSN-flag20E6) were subsequently kept on fresh mitomycin C-
treated feeder layer in NIKS complete medium and expanded for
4 to 8 passages.
Caspase- and ubiquitin-inhibitors
Transfected H1299 cells were incubated overnight with either
50 mM Z-VAD-FMK (general caspase inhibitor) or 25 mM
calpeptin (calpain inhibitor) before harvesting. These transfected
cells were alternatively incubated for 6 hours in the presence of the
proteasome inhibitor MG132 (20 mM) or the 20S proteasome
inhibitor b-lactone (Lactacystin 5 mM) (all Calbiochem, Darm-
stadt, Germany) before harvesting. HPV20E6-expressing NIKS
cell line was incubated overnight with 10 mM MG132.
Western blot analyses
Western blot was performed as described [40]. Total cellular
protein was extracted and subjected to Western blot analysis after
separation in 15% or 8% SDS-PAGE. For quantitation of the
respective proteins, as well as to control for transfection efficiency,
antibody staining for b-actin and b-galactosidase were respectively
included in each analysis. The primary antibodies used were anti-
Flag (cat#200472) (Stratagene, CA, USA), anti-p53 (sc-126), anti-
p63a (sc-8344), anti-p16 (sc-9968) and anti-PCNA (sc-56) (all
Santa Cruz, Heidelberg, Germany), anti-b-gal (cat#Z378A)
(Promega, Madison, USA), anti-b-actin (cat#691001) (ICN,
Aurora, Ohio, USA) and anti-pRB (cat#OP136) (Calbiochem,
Darmstadt, Germany). Primary antibodies against Apaf-1
(cat#4452), caspase-3 (cat#9662), caspase-9 (cat#9509), cas-
pase-8 (cat#9746), LC3B (cat#4108), Bak (cat#3792), Bax
(cat#2774), phospho-c-Jun (ser63) (cat#9261) and c-Jun
(cat#9165) were purchased from Cell Signaling (Frankfurt am
Main, Germany).
Apoptosis assays
Cells (with or without MG132 treatment) were collected by
trypsinization, washed with phosphate-buffered saline and stained
using an Annexin V-PE apoptosis Detection Kit I (BD Biosciences)
as described previously [13]. Early stage apoptosis was identified as
Annexin V positive(+)/7-AAD negative(2) population. Percent-
ages were determined in the FACScalibur system using FlowJo
software (Ashland, USA).
Silencing of p53 by siRNA
siRNA p53 (10 nM; cat#1024849) and control siRNA which
has no homology to any known mammalian gene (10 nM;
cat#1022563) was transfected into the NIKS cell line as previously
described [43]. Both reagents were purchased from Qiagen
(Hilden, Germany). Control-siRNA and mock transfections
(absence of siRNA) served as negative controls.
Cell proliferation as measured by EdU incorporation
Cell proliferation was measured in three independent assays by
EdU (5-ethynyl-29-deoxyuridine) incorporation using the Click-
iT
TM EdU Flow Cytometry Assay Kit (Invitrogen, Karlsruhe,
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treated with 10 mM EdU for 24 hours prior to staining with Alexa
Fluor 488 azide (cat#C35002, Invitrogen, Karlsruhe, Germany).
EdU incorporation was determined by FACScalibur using FlowJo
software (Ashland, USA).
Co-immunoprecipitation
Total protein was isolated from pLXSN-flagHPV20E6-NIKS
cells as described previously [40] for co-immunoprecipitation assays.
Lysates were pre-cleared to reduce background [44] and used for
immunoprecipitation by adding 4 mg of the respective antibodies
Cdk6, (Santa Cruz, Heidelberg, Germany), P16 (mtm, Heidelberg,
Germany) and PP2AC (Cell Signal, Frankfurt am Main, Germany),
followed by incubation for 1 h at 4uC on a rocking platform. Protein
A-agarose (25 ml bed volume) was subsequently added to each
immune complex and incubated overnight at 4uC. Reactions
without cell lysates served as negative control. Immunocomplexes
were washed according to the manufacturer’s protocol (Roche,
Mannheim Germany) before the immunoprecipitated proteins were
dissociatedfromthe beads byboiling for 3 min inone bed volumeof
elution buffer [126 mM Tris – HCl (pH 6), 20% glycerol, 4% SDS,
0.02% bromophenol blue, and 1% 2-mercaptoethanol]. The total
sample was used for Western blots analysis [45]. Interaction partners
with the immunoprecipitated proteins were visualized by Western
blot analysis using the following respective antibodies Cdk6, Cdk4
(Santa Cruz, Heidelberg, Germany) CyclinD1, PP2AB, PP2AC
(Cell Signaling, Frankfurt am Main, Germany) and P16 (mtm,
Heidelberg, Germany).
Methylation-specific PCR
Cellular DNA methylation was determined using the CpGeno-
me
TMDNA Modification kit (Millipore, Schwalbach, Germany).
Unmodified DNA was controlled for by amplification using W
(wild type) primers. Methylation status of p16 CpG islands was
analyzed by methylation-specific PCR amplification using the
CpG WIZH p16 Amplification Kit (Millipore, Schwalbach,
Germany). Primers for amplification of methylated p16 CpG
islands were (forward) 59-TTA TTA GAG GGT GGG GCG
GAT CGC-39 and (reverse) 59-GAC CCC GAA CCG CGA CCG
TAA-39 [46] and for unmethylated p16 CpG islands (forward) 59-
TTA TTA GAG GGT GGG GTG GAT TGT-39 and (reverse)
59-CAA CCC CAA ACC ACA AAC ATA A-39. Genomic DNA
of the colon cancer cell line RKO served as positive control in all
reactions. PCR was performed with the HotStarTaq DNA
polymerase kit (Qiagen, Hilden, Germany). Unmethylated p16
was amplified using the following conditions: 95uC for 5 min
followed by 30 cycles of amplification (denaturation at 95uC for
30 s, annealing at 62uC( 20.3uC/cycle) for 30 s and elongation at
72uC for 30 s) plus 10 additional cycles of annealing at 53uC and a
final extension at 72uC for 10 min [46]. Methylated p16 and wild
type p16 were amplified in 45 cycles: Initial denaturation at 95uC
for 12 min was followed by 10 cycles of denaturation at 94uC for
45 s, annealing at 68uC (methylated p16) or 60uC (wild type p16)
for 45 s and elongation at 72uC for 45 s. This was followed by 35
cycles of denaturation at 94uC for 45 s, annealing at 63uC for
methylated p16 or 58uC for wild type p16, elongation at 72uC for
45 s and additional a final extension step of 72uC for 10 min.
Results
p53 family-mediated stimulation or degradation of
cutaneous HPV E6 depends on HPV type
We had previously demonstrated the wtp53 family-mediated
degradation of HPV20E6 after ectopic expression of these proteins
in the p53-null cell line H1299 [13]. In the present study we
expressed N-terminal flag-tagged E6 proteins of a number of HPV
types from different genera using the same conditions. These E6
proteins included HPV4, HPV48 and HPV60 of the genus
Gamma-papillomavirus, from genus Beta-papillomavirus HPV5
and HPV20 (both species 1) and HPV38 (species 2), from genus
Alpha-papillomavirus HPV7 (species 1), HPV77 (species 2) and
HPV 27 (species 4), and HPV41E6 of genus Nu-papillomavirus.
Proteins were extracted and Western blot analyses performed
using antibodies against p53, DNp63a and flag for detection of
flag-tagged E6 proteins (Figure 1). Transfection efficiency was
measured by co-expression of b-galactosidase and the protein
loading controlled with b-actin. Expression of both wtp53 and
mutant p53R248W stimulated the expression of HPV4E6,
HPV48E6 and HPV60E6 (genus Gamma-papillomavirus). Co-
expression of HPV4E6 with DNp63a led to a higher stimulation of
the viral E6 when compared to HPV48E6 and HPV60E6, but less
than by p53 (Figure 1A).
The HPV types tested in genus Beta-papillomavirus reacted
differently (Figure 1B). HPV20E6 expression was reduced in the
presence of ectopically expressed wtp53, but protected by both
mutp53R248W and DNp63a expression as previously reported
[13]. This was similar when HPV5E6 was co-expressed with the
respective wtp53, mutp53R248W and DNp63a.H P V 3 8 E 6i n
contrast, was down-regulated by co-expression of either wtp53 or
DNp63a and stimulated by co-expression of mutp53R248W.
Differential results were also obtained for the HPV types
belonging to genus Alpha-papillomavirus (Figure 1C). HPV7E6
and HPV27E6 were both down-regulated by co-expression with
wtp53, whereas wtp53 expression increased the level of
HPV77E6. Co-expression of mutp53R248W stimulated E6
expression of all three these HPV types, whereas DNp63a co-
expression increased HPV7E6 and HPV27E6, but led to a
decrease in HPV77E6.
Expression levels of HPV41E6 (genus Nu-papillomavirus) were
hardly influenced by co-expression of any of the p53-family
members (Figure 1D). C-terminal flag-tagged HPV20E6 was also
tested. No difference was noted in comparison to the N-terminal
flag-tagged HPV20E6 with respect to the down-regulation by
wtp53, even though the obtained signal was weak (data not
shown). C-terminal HA-tagged protein levels of all HPVE6
proteins could not be detected by Western blot analyses despite
the demonstration of the respective mRNA production by RT-
PCR (Figure 1E).
Degradation of the respective HPV6 proteins
Caspase-3 is required for the degradation of HPV20E6 [13].
The degradation of the respective HPVE6 proteins in the presence
of over-expressed wtp53 may be induced through different
pathways. We therefore expressed the proteins in the p53-null
H1299 cell line in the presence of either a general caspase
inhibitor (Z-VAD-FMK), a calpain inhibitor (calpeptin) or
proteasome inhibitors (MG132 or b-lactone), respectively
(Figure 2). The reduction of HPV20E6 when co-expressed with
wtp53, was eliminated in the presence of the caspase inhibitor Z-
VAD-FMK. Calpeptin, MG132 or b-lactone in contrast, did not
notably influence HPV20E6 levels. Similar observations were
made when co-expressing HPV38E6 and wtp53 (Figure 2A).
Treatment of H1299 transfected cells with proteasome inhibitors
MG132 or b-lactone resulted in an increase of the respective
HPV5E6, HPV7E6 or HPV27E6 protein levels in comparison to
their levels under co-expression with wtp53 in untreated H1299
cells. Caspase-inhibitor Z-VAD-FMK seemed to rescue E6 levels
of HPV5 and HPV7 from over-expressed wtp53, whereas the
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exerted a neutral or slightly negative effect (Figure 2B).
These data also indicate a HPV type difference in relation to the
influence of cellular proteins involved in the degradation of the
respective HPVE6 proteins. The effect is again independent of
phylogenetic grouping.
Figure 1. p53 family-mediated stimulation or degradation of cutaneous HPVE6 is HPV type dependent. Expression of HPVE6 genes in
H1299 cells (p53-null) with co-expression of wtp53, mutp53R248W or DNp63a (1 mg each). HPV types included (A) HPV4E6, 48E6 and 60E6 of genus
Gamma-papillomavirus, (B) HPV5E6, 20E6 and 38E6 from genus Beta-papillomavirus, (C) HPV7E6, 27E6 and 77E6 from genus Alpha-papillomavirus
and (D) HPV41 from genus Nu-papillomavirus. Proteins were analysed by Western blot analyses and levels were quantified by Imagequant.
Histograms represent HPV E6 protein expression normalized against b-actin loading control. Empty vector pcDNA3.1 (+) was co-transfected to
equalize the total amount of transfected DNA. Transfection efficiency was controlled for by b-galactosidase expression. (E) RT-PCR [40,59]
demonstrating the respective mRNA of c-terminal HA-tagged HPVE6 genes.
doi:10.1371/journal.pone.0035540.g001
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DNp63a on HPV20E6 in human keratinocytes harbouring
endogenous wtp53
Degradation of HPV20E6 in the presence of ectopically
expressed wtp53 in the p53-null H1299, a small cell lung cancer
cell line, was used as model. This however raises the question
whether similar observations can be made in human keratinocytes
under the influence of endogenous wtp53 and p63. HPV20 does
not readily immortalize primary keratinocytes. Difficulties were
encountered in obtaining sufficient numbers of cultured primary
keratinocytes expressing HPV20E6 for repeat experiments. We
instead used the spontaneously immortalized human keratinocyte
cell line NIKS [42] which also harbours endogenous p53-family
members. Even though we demonstrated HPV20E6 mRNA by
RT-PCR after transient transfection into NIKS cells (Figure S1),
we failed to detect N-terminal flag-tagged HPV20E6 protein in
these cells. We therefore established NIKS cells constitutively
expressing N-terminal flag-tagged HPV20E6 using retroviral
constructs (pLXSN-flagHPV20E6). Cells were pooled after G418
selection. We established and used 4 individual HPV20E6
expressing cell lines in order to cover any influences exerted by
varying chromosomal integration loci. Similar cell lines were
established for N-terminal flag-tagged HPV41E6, HPV27E6,
HPV38E6 and HPV4E6, respectively. mRNA of the respective
E6 genes was demonstrated in each case in these cells by RT-PCR,
but only flagHPV20E6 and flagHPV41E6 proteins were detect-
able by Western blot analyses. We failed to detect expression of C-
terminal HA-tagged E6 protein in pLXSN-HPV20E6-, -HPV4E6-
or -HPV41E6-NIKS cells, respectively.
We restricted all further experiments in this study to the use of
the 4 lines established for pLXSN-flagHPV20E6 for two reasons:
detection of flagHPV20E6 in Western blot analyses and the
differing influence of the p53 family members on its expression.
Equal amounts of wtp53-, mtp53R248W- and DNp63a-
expressing constructs were transfected into the pLXSN-
flagHPV20E6 cells. Expression levels of the respective proteins
were measured in Western blot analyses. Co-transfection of b-
galactosidase controlled for transfection efficiency. Protein expres-
sion was standardized against b-actin and normalized against b-
galactosidase. Ectopically-expressed wtp53 and mutp53R248W
both down-regulated HPV20E6 in the presence of endogenous
p53 when compared to the flagHPV20E6 protein level (Figure 3).
These results are contrary to observations made in H1299 cells in
the absence of endogenous wtp53, where mutp53R248W had a
protective effect [13]. A possible explanation is that tetrameriza-
tion between endogenous wtp53 and mtp53R248W may lead to a
gain of wtp53 function for the mutant p53 protein [26]. Similarly,
ectopic expression of DNp63a at high levels in the keratinocytes
also led to down-regulation of HPV20E6. Here tetramerization of
Figure 2. Degradation of the respective HPVE6 proteins. Wtp53 was co-expressed in H1299 cells with (A) HPV20E6 or HPV38E6, and (B)
HPV5E6, HPV7E6 or HPV27E6. Transfected cells were treated with general caspase inhibitor Z-VAD-FMK (50 mM), calpeptin (calpain inhibitor, 25 mM)
or proteasome inhibitors MG132 (20 mM) or b-lactone (Lactacystin 5 mM) prior to harvesting. Proteins were analysed by Western blot analyses and
protein levels quantified by Imagequant. Histograms represent HPVE6 protein expression normalized against b-actin. Empty vector pcDNA3.1(+) was
co-transfected to equalize total amount of transfected DNA and transfection efficiency was controlled for by b-galactosidase expression.
doi:10.1371/journal.pone.0035540.g002
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neutralizing effect on the latter.
Other cellular factors also exert an influence on HPV20E6
protein expression
Endogenous p53 was partially silenced by transfecting siR-
NAp53 into pLXSN-flagHPV20E6 cells. Total elimination of p53
by siRNA is not possible under experimental conditions [47].
Surprisingly, the level of HPV20E6 was concomitantly down-
regulated in the presence of siRNAp53 in contrast to the negative
controls (untransduced, transfected with control-siRNA or mock
transfected cells) (Figure 4). These data indicate that cellular
factor(s) other than endogenous p53, may be involved in the
degradation of HPV20E6. Transduced cells were then treated
with MG132 to determine whether proteasomal degradation was
involved. This led to a further decrease of HPV20E6 protein after
Figure 3. Influence of over-expressed wtp53, mtp53R248W and DNp63a on HPV20E6 expression in human keratinocytes with
endogenous wtp53. HPV20E6 protein expression in pLXSN-flafHPV20E6-NIKS cells in the presence of wtp53, mtp53R248W or DNp63a (1 mg) as
measured by Western blot analyses. Protein levels were quantified by Imagequant and histograms represent HPVE6 protein expression normalized
against b-actin. Empty vector pcDNA3.1(+) was co-transfected to equalize total amount of transfected DNA and transfection efficiency was controlled
for by b-galactosidase expression.
doi:10.1371/journal.pone.0035540.g003
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untreated cell lines. Results point to a sensitivity of this unknown
cellular factor to proteasomal degradation. Interestingly, MG132
treatment alone did not influence endogenous p53 levels, whereas
silencing of the latter by siRNAp53 was strongly augmented under
MG132 treatment and independent of expression of HPV20E6
(Figure 4). We investigated whether other cellular proteins known
to be involved in protein degradation, may be involved in the
down-regulation of HPV20E6 and endogenous p53 in pLXSN-
flagHPV20E6 and control pLXSN cells in the presence or absence
of MG132 (Figure 4). Apaf-1, caspase-3, caspase-9 and caspase-8
were all activated in the presence of MG132 as measured by their
respective cleaved proteins, indicating activation of both extrinsic
and intrinsic apoptotic pathway in both cell lines. Similarly,
LC3BI was activated to LC3BII indicating involvement of
autophagy [48]. Activation of these proteins in the presence of
MG132 has previously been reported [49,50]. The HPV20E6 and
wtp53 levels were minimally reduced under these conditions.
Interestingly, wtp53 expression in MG132 treated cells was
decreased in the presence of HPV20E6 expression when
compared to control cells. We subsequently performed FACS
analyses in order to determine whether an apoptotic effect of these
proteins could lead to the reduction in HV20E6 protein (Figure 5).
The very low rate of apoptosis (range of 2%) measured in both cell
lines, with a slightly higher rate in pLXSN-flagHPV20E6 cells in
comparison to pLXSN cells (p,0.05), was significantly increased
in both cell lines after MG132 treatment (p,0.001). The presence
of siRNAp53 did not influence this apoptosis. Molecular regulators
of apoptosis and autophagy are inter-connected and can be
activated by a variety of death stimuli [51]. These results indicate
that the mere activation of pathways involved in apoptosis or
autophagy did not result in the reduced HPV20E6 and
endogenous p53 protein levels.
Previous studies reported that cutaneous HPVE6 prevented
apoptosis after UV exposure by inducing degradation of the pro-
apoptotic Bak protein and preventing release of AIF from
mitochondria [37,38]. Constitutive Bak was however not degraded
in the presence of HPVE6 [37]. In the present study neither Bak
nor Bax was degraded in the presence of HPV20E6 (Figure 4).
HPV20E6 expression leads to increased proliferation of
keratinocytes
As the low levels of apoptosis did not markedly influence growth
of the pLXSN-flagHPV20E6 cell line, we continued to explore
whether even low level HPV20E6 expression provides a
proliferative advantage to keratinocytes. EdU incorporation into
the cells was used to measure proliferation (Figure 6). Increased
proliferation rate of pLXSN-flagHPV20E6 cells was significantly
higher than in the pLXSN control cells (p,0.05) or untransfected
NIKS cells (p,0.05).
These results prompted us to investigate whether HPV20E6
expression influenced cellular proteins involved in cell cycle
regulation.
HPV20E6 does not influence interaction between cyclin-
D1 and cdk6
An important step in cell cycle control is the complex formation
between cyclin-D1 and the cyclin-dependent kinases cdk4/6 to
drive cells from the early to the late G1 phase of the cell cycle. The
INK4 family of cyclin-dependent kinase inhibitors (including
p16
INK4a) dysregulates this step by binding to and inactivating
cyclinD1-cdk4/6 complexes [52]. We investigated whether
HPV20E6 may contribute to cell proliferation by interacting with
cyclin-D1, cdk6 and/or p16
INK4a. We performed competitive co-
immunoprecipitation assays between HPV20E6 and these cellular
proteins. Cyclin-D1 and p16
INK4a were pulled down by cdk6
antibodies without involvement of HPV20E6 (Figure 7). Interest-
ingly, expression of HPV20E6 increased the protein levels of
cyclin-D1, cdk6 as well as p16
INK4a in comparison to the control
pLXSN cells. Inverse co-immunoprecipitation assays excluded
non-specific interactions. Only unmethylated p16 was present in
both pLXSN-flagHPV20E6 and pLXSN cell lines as demonstrat-
ed by methylation specific PCR analyses (Figure S2).
PP2A does not play a role in HPV20E6-induced
keratinocyte proliferation
PP2A is a major serine-phosphatase. SV40 small t-antigen binds
to the A subunit of PP2A by displacing its B subunit. This binding
induces upregulation of cyclin-D1 transcription which leads to cell
transformation [53,54]. We investigated whether HPV20E6 is able
to interact with PP2A in a similar way by performing co-
immunoprecipitation assays. We failed to demonstrate binding
between HPV20E6 with either the AC subunits or the B subunit of
PP2A (data not shown).
c-Jun enhances cell proliferation through the induction of
cyclin-D1 transcription, whereas PP2A represses AP-1 activity by
dephosphorylation of c-Jun on Ser63 [55]. We therefore also
determined the levels of both phosphorylated and un-phosphor-
ylated c-Jun in the pLXSN-flagHPV20E6 cells. The levels of both
forms of c-Jun were increased in the HPV20E6 expressing cells in
comparison to the pLXSN control cells (Figure S3).
pRB is phosphorylated in the presence of HPV20E6
expression
The inactivation of pRB leads to suppression of senescence
allowing the cell to maintain the proliferative state by entry into S-
phase [56]. Phosphorylation of pRB was increased in the presence
of HPV20E6 expression, as demonstrated by western blot analyses
(Figure 8), indicating inactivation of this protein.
Discussion
HPV infection, UV-exposure and mutations in wtp53 have
been considered as interacting factors in the pathogenesis of non-
melanoma skin cancer. DNA of a wide spectrum of HPV types,
mainly of the genera Beta- and Gamma-papillomaviruses has been
demonstrated not only in the malignant lesions, but also in normal
skin [3,4]. Recent data failed to demonstrate HPV transcription in
these lesions thereby posing the question whether these viruses are
actually involved in the pathogenesis of this disease [57]. We have
previously demonstrated that the activation or suppression of a
number of cutaneous HPV promoters by UV-irradiation is type
specific rather than genus- or species-specific [39]. This was
recently confirmed by others [36]. Chronic exposure of HPV20-
and HPV27E6/E7 transgenic mice to UV-irradiation resulted in
the formation of papillomas and malignant lesions of the skin [58].
Our previous studies demonstrated interplay between UV-induced
mutp53R248W, DNp63a and wtp53 in relation to the expression
of HPV20E6. Wtp53 mediated the caspase-3-dependent degra-
dation of HPV20E6 protein [13,40,59]. We now extended these
investigations to other HPV types of the genera Beta-, Gamma-
and Nu-papillomavirus. Co-expression with wtp53 exerted a very
distinct regulation for the individual cutaneous E6 genes. E6
proteins of all types from genus Gamma-papillomavirus tested
(HPV4, HPV48 and HPV 60) were up-regulated by wtp53, in
contrast to the E6 down-regulation of all Beta-papillomavirus
types tested (HPV5, HPV20 and HPV38). Wtp53 down-regulated
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genus-Alpha-papillomavirus. Mutp53R248W up-regulated expres-
sion of all HPVE6 proteins tested. HPV38E6 and HPV77E6 were
down-regulated by DNp63a whereas all other E6 proteins were
up-regulated. Down-regulation of the respective HPV E6 proteins
was type dependent and mediated either through caspase- and/or
proteasome pathways. HPV41E6 expression remained unaffected
by any of these p53-family members. These data underline the
diversity in intracellular mechanisms exerted by various papillo-
mavirus types, differing not only between genera, but even
between HPV types within a genus.
We had obtained these results by over-expressing the respective
proteins in a p53-null cell line. We now attempted to mimic the in
vivo situation as close as possible by repeating these experiments
using a spontaneously immortalized keratinocyte cell line (NIKS)
harbouring endogenous p53 and p63. Ectopic expression of both
mutp53R248W and DNp63a led to a down-regulation of
HPV20E6 in contrast to our previous data obtained in p53-null
cells, as well as in untransfected pLXSN-flagHPV20E6 cells. The
contact-mutant p53R248W acts as dominant negative after
tetramerization with wtp53. This complex re-localizes to the
nucleus. p63 localizes predominantly to the nucleus in the
presence of wtp53, but forms perinuclear aggregates when
tetramerizing with mutant p53R248W [26]. Re-localization of
these complexes may lead to altered function. An imbalance
between endogenous p53 and p63 in relation to over-expressed
Figure 4. Down-regulation of HPV20E6 is influenced by proteins other than those involved in apoptosis or autophagy. Western blot
analysis of cell lysates from pLXSN-flagHPV20E6- and pLXSN-NIKS cells after transfection with siRNAp53 (10 nM) or siRNA-NK (negative control siRNA,
10 nM) and incubation for 16 h with or without MG132 (10 mm). MG132 treatment induced activation of apaf-1, caspase-8, caspase-9 and caspase-3,
as well as the autophagy marker LC3BII. Histograms represent HPV20E6 and wtp53 protein levels normalized against b-actin.
doi:10.1371/journal.pone.0035540.g004
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have influenced the functions of these proteins.
Endogenous p53 was partially silenced by transfecting siR-
NAp53 into pLXSN-flagHPV20E6 and pLXSN cells. Surprisingly
this resulted in a reduced expression of HPV20E6 as well. MG132
treatment of these cells led to the expected activation of several
cellular proteins involved in both apoptotic and autophagic
pathways, but did not alleviate the down-regulation of HPV20E6.
Partial silencing of p53 by addition of siRNAp53 did not influence
the increased apoptosis in MG132-treated pLXSN-flagHPV20E6
and pLXSN cells as measured by FACS analyses. We therefore
conclude that HPV20E6 expression is modulated by additional,
yet unidentified, cellular protein(s) which are not necessarily
involved in apoptosis or autophagy.
HPV20E6 expression induced proliferation of the pLXSN-
flagHPV20E6 cells. In an attempt to identify cellular proteins
involved in cell cycle control which may be affected by the
expression of HPV20E6, we investigated cyclin-D1, cdk6,
p16
INK4a, PP2A and pRB. Cyclin-D1 and ckd6 enhance
keratinocyte proliferation by phosphorylation of down-stream
targets including pRB [60,61]. The increased pLXSN-
flagHPV20E6 proliferation may be a consequence of increased
expression of cell cycle proteins indirectly induced by HPV20E6
expression. However, p16
INK4a is active and its expression
Figure 5. HPV20E6 expression itself does not induce apoptosis. pLXSN-flag20E6- or pLXSN- NIKS cells were incubated overnight with MG132
(10 mM). Apoptosis was subsequently measured by flow cytometry of Annexin V-staining cells (Annexin V+/7-AAD-) in three independent
experiments. Apoptosis [Annexin V(+)/7-AAD(2)] was significantly increased in both pLXSN20E6- and pLXSN-NIKS cells after MG132 treatment
(p,0,001), but no significant difference (p=0,042) was seen between HPV20E6-expressing cells in comparison to controls. Statistical analyses were
performed using the student t-test. * - p,0.05, *** - p,0.001.
doi:10.1371/journal.pone.0035540.g005
Figure 6. HPV20E6 expression increases proliferation. Equal densities of pLXSN-20E6 and pLXSN cells were incubated with 10 mM EdU for
24 hours. EdU-7AAD staining was analysed by FACS for the percentage of proliferating cells as indicated in the histogram. Statistical analyses (student
t-test) of three independent experiments indicate a significant increase in the proliferation rate of pLXSN-20E6 cells (*p,0.05) in comparison to
pLXSN cells and untransduced NIKS cells.
doi:10.1371/journal.pone.0035540.g006
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INK4a to
the CDK complexes which would negatively regulate prolifera-
tion. HPV20E6 did not compete for this interaction of p16
INK4a
with cyclin-D1 or cdk6. p16
INK4a similarly activates pRB by
preventing its phosphorylation. However, the level of pRB
phosphorylation in the HPV20E6 expressing cells would be
sufficient to override the cytokenetic block induced by the
p16
INK4a/pRB pathway [62].
HPV16E7 binds to subunits of PP2A thereby sequestering de-
phosphorylation of down-stream targets involved in proliferation
[63]. PP2A does not seem to be directly involved in our system.
HPV20E6 does not bind either A or B subunits and PP2A in turn
does not influence the phosphorylation of c-Jun which is necessary
for the activation of cyclin-D1 transcription. The levels of both p-
c-Jun and c-Jun were elevated in the HPV20E6 expressing cells.
The p53 and p63 proteins (including p53 mutants) are involved
in a plephora of cellular functions [24,26–28,64]. Many of these
functions are attributed to complex interactions between p53 and
p63 isoforms and their mutants, which in turn influence the
activity of downstream targets involved in development and
proliferation. A delicate balance between protein levels of
individual cellular factors is very important and ratios between
proteins often determine biological outcome [27]. The present
study demonstrates the diverse influence of p53 family members
on individual cutaneous HPVE6 proteins. HPV20E6 expression
also resulted in varying protein levels of factors involved in
proliferation and differentiation. Additional investigation for each
cutaneous HPV type is needed to determine the exact role of
individual viral proteins in relation to cellular factors involved in
proliferation and differentiation. These observations underline the
diverse clinical manifestations induced by individual cutaneous
HPV types.
Supporting Information
Figure S1 RT-PCR demonstrating expression of
HPVE6. N-terminal-flag-HPVE6 of the respective HPV types
was transiently transfected into NIKS cells. Total RNA was
Figure 7. HPV20 E6 does not compete for binding of cdk6 to cyclinD1 or to p16
INK4a. Total protein extracts from pLXSN-flag20E6- or
pLXSN-NIKS cells were immuno-precipitated onto cdk6 protein. Protein A agarose precipitated with cdk6 antibody alone served as negative control.
Levels of input proteins flagHPV20E6, p16, cyclinD1 and cdk6 were visualized by western blot analyses. Histograms represent input protein
expression normalized to b-actin serving as loading control.
doi:10.1371/journal.pone.0035540.g007
Figure 8. HPV20E6 increases the expression of ppRB. Western
blot analyses of the protein level of pRb and ppRb in pLXSN-flag20E6
and pLXSN transduced NIKS cells. The pRb and ppRb protein level were
quantified by Imagequant. Histograms were adjusted for b-actin which
was used as a loading control.
doi:10.1371/journal.pone.0035540.g008
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internal control.
(TIF)
Figure S2 HPV20E6 influenced neither the methylated
nor unmethylated p16. Methylation status of the bisulfied p16
CpG islands was analysed by PCR amplification using primers
specific for methylated or unmethylated p16. RKO was used as
positive control of methylated p16. W (wild type) primers amplify
only DNA which is not chemically modified and serve as a control
for the efficiency of chemical modification. Gene expression was
measured from three independent experiments and histograms
represent unmethylated p16 normalized against wild type p16. No
significant difference (student t-test) was determined between
pLXSN-flag20E6 NIKS cells and the respective controls: (1)
untransfected NIKS cells (2) pLXSN-NIKS cells (3) pLXSN-
flag20E6-NIKS cells and (4) RKO cells.
(TIF)
Figure S3 HPV 20E6 up-regulated c-Jun and p-c-Jun
protein levels. c-Jun and p-c-Jun levels in pLXSN-flag20E6 and
pLXSN-NIKS cells by Western blot analyses. Histograms indicate
levels adjusted against b-actin which served as loading control.
(TIF)
Table S1 Primers for plasmid design. Primers used for
PCR amplification of N-terminal or C-terminal flag-tagged E6
and C-terminal hemagglutinin (HA)-tagged E6. Full-length
genomes were used as template for the E6 amplification of HPV
types 4, 5, 7, 20, 27, 38, 41, 48, 60 and 77.
(DOC)
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